Covid-19 roundup: Cit­ing a lack of need, Gilead cuts remde­sivir study; No­vavax vac­cine pro­duc­tion slowed due to sup­ply short­ages

Gilead is halt­ing its remde­sivir study in high-risk, non-hos­pi­tal­ized Covid-19 pa­tients af­ter a de­ci­sion that the study no longer ad­dress­es an un­met need, a state­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER